IQVIA (NYSE:IQV) Given New $255.00 Price Target at UBS Group

IQVIA (NYSE:IQV) had its target price trimmed by UBS Group from $260.00 to $255.00 in a research note published on Friday morning,Benzinga reports. The firm currently has a buy rating on the medical research company’s stock.

Several other brokerages have also commented on IQV. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $270.00 price objective on shares of IQVIA in a research report on Wednesday, December 11th. StockNews.com downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Thursday, November 28th. Robert W. Baird decreased their target price on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a research report on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft dropped their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Stephens initiated coverage on IQVIA in a report on Friday, December 20th. They issued an “overweight” rating and a $250.00 price objective for the company. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $252.39.

IQVIA Price Performance

IQV stock opened at $208.13 on Friday. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.81 and a current ratio of 0.84. The business has a 50-day simple moving average of $200.67 and a two-hundred day simple moving average of $219.40. The company has a market capitalization of $37.78 billion, a P/E ratio of 27.75, a price-to-earnings-growth ratio of 2.25 and a beta of 1.48. IQVIA has a 52-week low of $187.62 and a 52-week high of $261.73.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts expect that IQVIA will post 10.81 EPS for the current fiscal year.

Insider Buying and Selling at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the stock in a transaction dated Tuesday, December 3rd. The shares were purchased at an average cost of $200.58 per share, with a total value of $255,739.50. Following the completion of the acquisition, the director now directly owns 1,275 shares in the company, valued at $255,739.50. This trade represents a ∞ increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On IQVIA

A number of hedge funds have recently bought and sold shares of the business. Capital Performance Advisors LLP bought a new stake in shares of IQVIA in the third quarter worth approximately $27,000. Synergy Asset Management LLC bought a new stake in IQVIA in the 4th quarter worth approximately $33,000. Avior Wealth Management LLC raised its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after buying an additional 87 shares during the last quarter. Assetmark Inc. lifted its holdings in shares of IQVIA by 612.5% during the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock valued at $54,000 after buying an additional 196 shares during the period. Finally, UMB Bank n.a. grew its holdings in shares of IQVIA by 74.4% in the third quarter. UMB Bank n.a. now owns 232 shares of the medical research company’s stock worth $55,000 after acquiring an additional 99 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.